Get the Daily Brief
Latest Biotech News
Alzheimer’s biomarker trajectories
A Nature Communications study mapped how tau species evolve in both plasma and cerebrospinal fluid (CSF) during Alzheimer’s disease progression, providing new “trajectories” for biomarkers rather...
AI drug design for protein-targeted molecules
University of Virginia researchers unveiled YuelDesign, YuelPocket and YuelBond, a set of AI tools that use diffusion models to generate drug-like molecules tailored to specific protein...
Protein degraders: pipeline options and new ADC/degrader tie-ups
Gilead exercised an option license on a Kymera Therapeutics protein-degrading program targeting CDK2, while Roche expanded its protein-degrader ambitions via a new collaboration with C4...
FDA regulatory decision on AI device premarket pathway
The FDA denied a petition from Harrison.ai seeking a partial exemption from premarket review for certain diagnostic/detection AI devices, preserving the existing regulatory status quo. The...
Obesity GLP-1 pill launches and competitive pricing dynamics
Eli Lilly launched Foundayo, an oral obesity treatment approved by the FDA last week, escalating competition with Novo Nordisk in the oral GLP-1 market. Lilly set the lowest dose at $149 a month...
Biopharma real-world data deal expands Gilead–Tempus partnership
Tempus announced an expanded, multi-year collaboration with Gilead, giving the pharma access to additional multimodal real-world cancer data and Tempus’s AI platform. The companies previously...
Protein degradation platform financing and clinical pipeline
Life Biosciences raised a fully subscribed $80 million Series D to advance ER-100 in phase I trials, targeting biological aging through partial epigenetic reprogramming. The capital funds...
Biopharma financing outlook: Q1 2026 rebound and IPO traction
Biopharma financings rebounded strongly in Q1 2026, reaching $22.82 billion, up roughly 74% year over year, according to reported totals. The data show financing activity recovering from a softer...
FDA device safety: warning letter over angiographic control syringes
The FDA issued a warning letter to Medline Inc. over identified issues with its Namic brand angiographic control syringes and manifolds used with radiographic contrast media. The agency said the...
Private financing: Jeito’s €1.2B fund for European clinical-stage biotechs
Jeito Capital closed its second fund at $1.2 billion (€1 billion+), targeting 15 to 20 European clinical-stage biopharma companies. The firm said the larger pool allows higher average ticket...
GLP-1 oral obesity drug launch sparks head-to-head competitive pressure
Eli Lilly launched Foundayo, its long-anticipated oral obesity medicine, after receiving FDA approval last week and began offering the lowest dose at $149 per month for self-pay customers. The...
Rising 340B and Medicaid reconciliation risk under US pricing rules
Pharma finance and access leaders highlighted mounting complexity at the 340B and Medicaid intersection, pointing to reconciliation risk that can produce prohibited “double-dipping” scenarios....
Gilead expands real-world data and AI collaboration with Tempus
Gilead expanded its Tempus partnership, granting the drugmaker broader access to Tempus’s multimodal real-world cancer dataset library and its AI platform. Tempus said the multi-year collaboration...
Gilead pays for molecular glue degrader option from Kymera
Gilead agreed to pay Kymera Therapeutics $45 million to exercise an option on a preclinical anticancer molecular glue degrader, adding another oncology asset to a pipeline built through...
Neuroblastoma target points to nNOS–mTOR axis for therapy development
Researchers from The Hebrew University of Jerusalem reported that blocking neuronal nitric oxide synthase (nNOS) suppresses neuroblastoma growth by disrupting an AKT–TSC–mTOR signaling cascade....
Precision nasal oxytocin and controlled delivery technologies enter mental health/neurology space
Insilico-accelerated drug discovery aside, one clinically oriented delivery theme that emerged in the dataset is long-term intranasal oxytocin work aimed at stabilizing exposure beyond short-lived...
Neuroinflammation and cardiac fibrosis via engineered dendritic cells
A preclinical report described engineered dendritic cells that prevent cardiac remodeling, targeting the fibrotic processes that drive progression to heart failure. The approach is positioned...
Grail and Epic expand ordering of early cancer blood test inside EHR workflows
Grail partnered with Epic to integrate access to the Galleri multi-cancer early detection test directly within Epic electronic health record platforms. Under the agreement, clinicians can order...
Sidewinder Therapeutics raises $137M for precision bispecific ADCs
Sidewinder Therapeutics emerged from stealth with an oversubscribed $137 million Series B, backed by investors including OrbiMed and Novartis’ venture arm. The San Diego biotech is developing...
Neurocrine to acquire Soleno for $2.9B, expands rare endocrinology portfolio
Neurocrine Biosciences agreed to acquire Soleno Therapeutics for $2.9 billion in cash, a deal designed to scale a marketed therapy for Prader-Willi syndrome. The transaction includes Soleno’s...